Cargando…
Factors associated with sepsis risk in immune-mediated inflammatory diseases receiving tumor necrosis factor inhibitors: a nationwide study
BACKGROUND: Risk factors for sepsis have not been assessed in patients receiving tumor necrosis factor-alpha inhibitors (TNFi) for immune-mediated inflammatory diseases (IMIDs) who are vulnerable to serious/hospitalized infections. METHODS: Data from 2003–2017 were obtained from Taiwan’s National He...
Autores principales: | Chao, Wen-Cheng, Wang, Chen-Yu, Hsu, Bo-Chueh, Lin, Ching-Heng, Huang, Wen-Nan, Chen, Yi-Hsing, Wu, Chieh-Liang, Chen, Hsin-Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7298427/ https://www.ncbi.nlm.nih.gov/pubmed/32595776 http://dx.doi.org/10.1177/1759720X20929208 |
Ejemplares similares
-
Tuberculosis and targeted synthetic or biologic DMARDs, beyond tumor necrosis factor inhibitors
por: Evangelatos, Gerasimos, et al.
Publicado: (2020) -
Mortality risk prediction in lupus patients complicated with invasive
infection in the emergency department: LUPHAS score
por: Wu, Wanlong, et al.
Publicado: (2019) -
JAK inhibitors and infections risk: focus on herpes
zoster
por: Sunzini, Flavia, et al.
Publicado: (2020) -
Oral disease-modifying antirheumatic drugs and immunosuppressants with antiviral potential, including SARS-CoV-2 infection: a review
por: Tsai, Y. C., et al.
Publicado: (2020) -
Reactivation of hepatitis B virus infection in rheumatic diseases: risk and management considerations
por: Koutsianas, Christos, et al.
Publicado: (2020)